• 新闻与活动

    学术成果

Computational Insights into Kinetic Hindrance Affecting Crystallization of Stable Forms of Active Pharmaceutical Ingredients

Cryst. Growth Des. 2020, 20, 3, 1512–1525

A computational investigation of the potential source of kinetic hindrance for the late appearance of pharmaceutically relevant stable forms of ritonavir, rotigotine, ranitidine hydrochloride, and pharmaceutical compound A was performed along the crystallization coordinates of the relative rates of conformational interconversion, crystal nucleation, and growth. Conformational distribution, classical nucleation, and growth morphology theories were utilized, respectively, to compare the results with those of polymorphic systems, famotidine, nimodipine, paracetamol, indomethacin, tolfenamic acid, and mebendazole for which kinetic hindrance of the stable forms was not reported. The results did not support a potential mechanism of kinetic hindering of the stable polymorphic form due to nucleation and growth limited crystallization. However, a low population of crystallographic conformations of the stable forms in solution allowed us to distinguish the behavior of the late-appearing stable systems from other polymorphic systems. To account for the low crystallographic conformer population as the potential source for kinetic hindrance, we suggest that self-association of the monomeric active pharmaceutical ingredients molecules precedes over nucleation in solution. As an implication to crystal structure prediction studies, it is suggested to complement the analysis of the lattice energy landscape of conformational polymorphs by the prediction of crystallographic conformers distribution in the gas phase and in solvents of potential interest.

想继续了解更多?

联系我们

我们期待您的留言

让我们知道如何为您提供帮助,我们团队将24小时内与您联系!

姓名
电话
邮箱
国家/地区
北京市
天津市
上海市
重庆市
河北省
山西省
辽宁省
吉林省
黑龙江省
江苏省
浙江省
安徽省
福建省
江西省
山东省
河南省
湖北省
湖南省
广东省
海南省
四川省
贵州省
云南省
陕西省
甘肃省
青海省
台湾省
内蒙古自治区
广西壮族自治区
西藏自治区
宁夏回族自治区
新疆维吾尔自治区
香港特别行政区
澳门特别行政区
从事行业
小分子药物研发
抗体药物研发
CRO/CDMO
投融资机构
高校/研究院所/医院
园区
生物医药产业
感兴趣的业务
小分子药物发现
抗体药物发现
药物固体形态研发
化学合成服务(含自动化合成)
实验室自动化解决方案
所在公司
是否需要业务人员跟进?
暂不需要
验证码

我已阅读并同意 yl23455永利官网隐私政策法律声明